Drug intelligence / Profile preview

disitamab vedotin + carboplatin + bevacizumab

Development stage: Unknown
Lead developer: RemeGen
Modality: Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

disitamab vedotin + carboplatin + bevacizumab is a combination therapy regimen being evaluated for the treatment of HER2-expressing, HRD-negative high-risk ovarian cancer. The regimen consists of disitamab vedotin (RC48), a HER2-targeted antibody-drug conjugate (ADC) composed of a humanized anti-HER2 antibody conjugated to the microtubule-disrupting agent monomethyl auristatin E (MMAE); carboplatin, a platinum-based chemotherapeutic agent that induces DNA cross-linking and apoptosis; and bevacizumab, a recombinant humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF) to inhibit tumor angiogenesis. This combination is currently being studied in a Phase II clinical trial led by the Jiangsu Cancer Institute & Hospital as a first-line and maintenance therapy to improve outcomes in patients with specific molecular profiles of ovarian cancer.

Brand names: AidixiAvastinParaplatin
Other names: disitamab vedotin + platinum + bevacizumabRC48 + platinum + bevacizumab

Targets

VEGFA (Vascular endothelial growth factor A)TUBB (Tubulin (alpha and beta subunits))ERBB2 (Erb-b2 receptor tyrosine kinase 2)DNA

Beyond the preview

Go deeper on disitamab vedotin + carboplatin + bevacizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on disitamab vedotin + carboplatin + bevacizumab.

Explore the full profile